NCT05848700View on ClinicalTrials.gov

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856 Tablet

DRUG

Placebo

Placebo Tablet

Trial Locations (7)

30331

Atlanta Center for Medical Research, Atlanta

33016

Behavioral Clinical Research, Inc, Miami Lakes

33334

Research Centers of America at Fort Lauderdale Behavioral Health Center, Oakland Park

44720

Neuro-Behavioral Clinical Research, Inc, North Canton

72211

Woodland International Research Group, LLC, Little Rock

72758

Woodland Research Northwest, Rogers

75080

Pillar Clinical Research, LLC, Richardson

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT05848700 - A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia | Biotech Hunter | Biotech Hunter